Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide Added to Standard Induction Therapy in Older and Very Poor Risk AML
2009-013094-17Phase 2Active
- Sponsor
- HOVON
- Start
- Aug 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of lenalidomide in acute myeloid leukemia (AML) and myelodysplastic syndrome with excess blasts (MDS-EB) (2 arms), sponsored by HOVON. Primary endpoint: Incidence of dose-limiting toxicity. Started Aug 2009; status: active.
02
Drugs
lenalidomide
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome with excess blasts (MDS-EB)
Beyond the preview
Go deeper on 2009-013094-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013094-17.